The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...

Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli ... Lilly closed out the year by snagging a key new approval for Zepbound in obstructive sleep apnea (OSA ...

Eli Lilly and Company (NYSE ... only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity.1 Zepbound may help adults with moderate-to-severe ...

This growing demand for these treatments has positioned Eli Lilly well in the market, especially with the recent FDA approval of Zepbound for the treatment of obstructive sleep apnea, a common ...

The female hormone estrogen appears to promote binge drinking in women, a new mouse study published recently in the journal ...

A new quick-and-easy nasal swab test for kids can diagnose the specific immune system drivers behind their asthma, ...